Back to top
more

Illumina (ILMN)

(Real Time Quote from BATS)

$94.60 USD

94.60
435,404

+0.17 (0.18%)

Updated Aug 7, 2025 12:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Iovance Biotherapeutics (IOVA) Jumps: Stock Rises 5.1%

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

    Zacks Equity Research

    CVS Health's PBM Selling Season Remains Solid, Retail Grows

    by Zacks Equity Research

    CVS Health (CVS) significantly advances more than halfway through its 2019 renewals. Also, strong year-over-year Retail/LTC comparisons are encouraging.

      Zacks Equity Research

      Pacific Biosciences to Gain From New Genome Sequencing Tools

      by Zacks Equity Research

      Pacific Biosciences' (PACB) new multiplexing kit to make genome sequencing faster and cost-effective.

        Zacks Equity Research

        Here's Why You Should Invest in Genomic Health (GHDX) Now

        by Zacks Equity Research

        Genomic Health (GHDX) gains ground on promising reimbursement prospects for its Oncotype DX breast cancer test and solid international scenario.

          Zacks Equity Research

          ResMed Reports Positive Results for Bilevel PAP Device Study

          by Zacks Equity Research

          Positive results from the Bilevel Rescue study are expected to boost the uptake of ResMed's (RMD) bilevel devices.

            Zacks Equity Research

            STERIS (STE) Benefits From Core Business Expansion, Buyouts

            by Zacks Equity Research

            STERIS' (STE) strong organic growth across specialty services, life sciences and applied sterilization segments raises optimism on the stock.

              Zacks Equity Research

              Amedisys (AMED) Buys Back 2.4M Shares From KKR, Stock Up

              by Zacks Equity Research

              Amedisys (AMED) works on its strategy to deploy capital in an accretive manner, maintaining low leverage and substantial borrowing capacity for future investment.

                Zacks Equity Research

                Medtronic's (MDT) CRHF Arm Growth Strong, Rising Costs a Woe

                by Zacks Equity Research

                The gradually stabilizing Cardiac Rhythm & Heart Failure (CRHF) market increases investor confidence in the Medtronic (MDT) stock.

                  Zacks Equity Research

                  Bristol-Myers (BMY) Reports Data from CheckMate-214 Study

                  by Zacks Equity Research

                  Bristol-Myers Squibb (BMY) announces encouraging data from the phase III CheckMate -214 study.

                    Zacks Equity Research

                    Boston Scientific Grows on New Products Amid Recall Issues

                    by Zacks Equity Research

                    Boston Scientific's (BSX) 2018 guidance raises optimism for the company's near-term prospects.

                      Zacks Equity Research

                      Bruker Unveils New Mass-Spectrometry Products, Boosts CALID

                      by Zacks Equity Research

                      Bruker's (BRKR) mass-spectrometry business within its CALID group rides high on strong sales performances in recent times.

                        Zacks Equity Research

                        The Zacks Analyst Blog Highlights: Illumina, Athersys, EyePoint Pharmaceuticals, Rhythm Pharmaceuticals and Ligand Pharmaceuticals

                        by Zacks Equity Research

                        The Zacks Analyst Blog Highlights: Illumina, Athersys, EyePoint Pharmaceuticals, Rhythm Pharmaceuticals and Ligand Pharmaceuticals

                          Zacks Equity Research

                          Abbott Launches Afinion 2 Analyzer Rapid Test in the U.S.

                          by Zacks Equity Research

                          Abbott's (ABT) recently-launched Afinion 2 analyzer system is likely to boost top-line contributions from the Diagnostic division.

                            Zacks Equity Research

                            Illumina (ILMN) Grows on Innovation & Strategic Partnerships

                            by Zacks Equity Research

                            Illumina's (ILMN) alliances with Bristol-Myers Squibb and Loxo Oncology to reap positive results in oncology.

                              Gourav Kanti Bagchi headshot

                              "Right To Try" Brings Good News for Biotech Sector: 5 Picks

                              by Gourav Kanti Bagchi

                              Passage of the Right To Try law and WHO's focus on assessing the quality of bio-similar drugs is expected to benefit biotech stocks.

                                Zacks Equity Research

                                Catalyst's Fridapse Gets Priority Review by FDA, Shares Up

                                by Zacks Equity Research

                                The FDA grants Priority Review to Catalyst's (CPRX) lead pipeline candidate, Firdapse, and set an action date of Nov 28, 2018.

                                  Zacks Equity Research

                                  Here's Why You Should Invest in Baxter International Now

                                  by Zacks Equity Research

                                  Strategic buyouts consistently help Baxter (BAX) gain market traction. Recently, the company completes the consolidation of both RECOTHROM and PREVELEAK.

                                    Zacks Equity Research

                                    ResMed's (RMD) HEALTHCAREfirst Buyout to Boost SaaS Business

                                    by Zacks Equity Research

                                    Integration of HEALTHCAREfirst's solutions suite with ResMed's (RMD) SaaS portfolio will help manage the burgeoning population and provide benefits to patients.

                                      Zacks Equity Research

                                      Novo Nordisk's Oral Ozempic Positive in Diabetes Study

                                      by Zacks Equity Research

                                      Novo Nordisk's (NVO) oral formulation of Ozempic acts better in lowering blood sugar levels in adults with type II diabetes than Eli Lilly's Jardiance, in the second phase IIIa study, PIONEER 2.

                                        Zacks Equity Research

                                        Bayer's Generic Competition, Pipeline Setback Issues Remain

                                        by Zacks Equity Research

                                        Generic threats/competition for many of its products remain a concern for Bayer (BAYRY).

                                          Zacks Equity Research

                                          Here's Why You Should Add ResMed (RMD) to Your Portfolio Now

                                          by Zacks Equity Research

                                          With a view to consistently lead the SDB market and boost the company's sales, ResMed (RMD) sets sights on product development and innovation.

                                            Zacks Equity Research

                                            Here's Why STERIS (STE) Stock is a Must Buy at the Moment

                                            by Zacks Equity Research

                                            STERIS (STE) gains ground on strategic buyouts and divestments.

                                              Zacks Equity Research

                                              Myriad Genetics' Planned Counsyl Buyout to Widen Portfolio

                                              by Zacks Equity Research

                                              Myriad Genetics (MYGN) plans to retain Counsyl as a wholly-owned subsidiary post the successful completion of the acquisition.

                                                Zacks Equity Research

                                                Zacks.com featured highlights include: Marine Products, Illumina, Chemed, Surmodics and MAM

                                                by Zacks Equity Research

                                                Zacks.com featured highlights include: Marine Products, Illumina, Chemed, Surmodics and MAM

                                                  Zacks Equity Research

                                                  IDEXX's (IDXX) Catalyst Uptake Remains Strong & Boosts CAG

                                                  by Zacks Equity Research

                                                  Solid organic growth trend within IDEXX's (IDXX) CAG revenues to sustain on the back of a strong global placement of high-premium Catalyst instruments.